Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LEZ763
- Development stage
- Phase 2
- Lead developer
- Novartis
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
LEZ763 is an investigational small molecule drug developed by Novartis for the treatment of type 2 diabetes mellitus. It acts as an agonist of GPR119 (glucose-dependent insulinotropic receptor), a target involved in glucose homeostasis and insulin secretion. The drug was designed to improve glycemic control by stimulating insulin release in a glucose-dependent manner. Clinical development included phase 1/2 trials assessing safety, tolerability, pharmacokinetics, and pharmacodynamics in both healthy volunteers and patients with type 2 diabetes. Development for this indication has been discontinued[2][3][4].
- Other names
- LEZ763LEZ-763LEZ 763
02
Targets
GPR119 (Glucose-dependent insulinotropic receptor)
Beyond the preview
Go deeper on LEZ763.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LEZ763.